Migra Therapeutics
Migra Therapeutics is a biopharmaceutical company founded in 2018, dedicated to developing innovative drug delivery platforms and targeted therapies for advanced and drug-resistant solid tumor cancers. Their mission focuses on clinical translation and commercialization of novel nanoparticle-based treatments, with a particular emphasis on overcoming drug delivery barriers in cancer therapy.
Industries
Nr. of Employees
small (1-50)
Products
Receptor-targeted stroma-penetrating hyaluronic acid nanoparticle for pancreatic cancer (investigational)
An investigational hyaluronic acid-based, receptor-targeted, stroma-penetrating nanoparticle platform formulated to deliver chemotherapeutic payloads to drug-resistant pancreatic tumors.
Receptor-targeted stroma-penetrating hyaluronic acid nanoparticle for pancreatic cancer (investigational)
An investigational hyaluronic acid-based, receptor-targeted, stroma-penetrating nanoparticle platform formulated to deliver chemotherapeutic payloads to drug-resistant pancreatic tumors.
Services
Design and execution of preclinical studies to validate targeted nanoparticle therapeutics and support regulatory filings for first-in-human trials.
Standardized production and protocol development for polymeric nanoparticle carriers, tumor-targeting ligand production, and recombinant proteins.
Design and execution of preclinical studies to validate targeted nanoparticle therapeutics and support regulatory filings for first-in-human trials.
Standardized production and protocol development for polymeric nanoparticle carriers, tumor-targeting ligand production, and recombinant proteins.
Expertise Areas
- Targeted drug delivery
- Nanoparticle therapeutics
- Stroma-penetrating delivery strategies
- Preclinical tumor models and in vivo imaging
Key Technologies
- Polymeric nanoparticle platforms
- Hyaluronic acid-based nanoparticle carriers
- Protease-mediated extracellular matrix degradation
- Receptor-targeted ligand functionalization